Kelsey Goodwin
Stock Analyst at Guggenheim
(1.95)
# 3,017
Out of 4,884 analysts
15
Total ratings
50%
Success rate
2.85%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kelsey Goodwin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| URGN UroGen Pharma | Maintains: Buy | $15 → $30 | $13.58 | +120.91% | 3 | Jun 13, 2025 | |
| IPSC Century Therapeutics | Reiterates: Buy | n/a | $0.56 | - | 3 | Mar 28, 2025 | |
| GNLX Genelux | Initiates: Buy | $8 | $2.98 | +168.46% | 1 | Oct 29, 2024 | |
| NUVL Nuvalent | Maintains: Buy | $99 → $105 | $80.48 | +30.47% | 2 | Sep 16, 2024 | |
| MGNX MacroGenics | Downgrades: Neutral | n/a | $1.46 | - | 1 | Jul 31, 2024 | |
| ACLX Arcellx | Maintains: Buy | n/a | $67.16 | - | 3 | Jun 20, 2023 | |
| LEGN Legend Biotech | Initiates: Neutral | n/a | $35.64 | - | 1 | Oct 31, 2022 | |
| IOVA Iovance Biotherapeutics | Initiates: Neutral | n/a | $1.75 | - | 1 | Oct 31, 2022 |
UroGen Pharma
Jun 13, 2025
Maintains: Buy
Price Target: $15 → $30
Current: $13.58
Upside: +120.91%
Century Therapeutics
Mar 28, 2025
Reiterates: Buy
Price Target: n/a
Current: $0.56
Upside: -
Genelux
Oct 29, 2024
Initiates: Buy
Price Target: $8
Current: $2.98
Upside: +168.46%
Nuvalent
Sep 16, 2024
Maintains: Buy
Price Target: $99 → $105
Current: $80.48
Upside: +30.47%
MacroGenics
Jul 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.46
Upside: -
Arcellx
Jun 20, 2023
Maintains: Buy
Price Target: n/a
Current: $67.16
Upside: -
Legend Biotech
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $35.64
Upside: -
Iovance Biotherapeutics
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $1.75
Upside: -